Recombinant Tumor Enzyme Specific Interferon α-2b Fc Fusion (Livzon Pharmaceutical Group)

重组肿瘤酶特异性干扰素α-2b Fc融合蛋白（丽珠单抗）

Report date: 2024/07/31 16:36:58

Base Information

Drug NameRecombinant Tumor Enzyme Specific Interferon α-2b Fc Fusion (Livzon Pharmaceutical Group)

Drug Alias NameA 01（Livzon Pharmaceuticals）A-01

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionImmunoglobulin G agonists

TargetsImmunoglobulin G

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

China Registration ClassClass 1 therapeutic biologic in China

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsSolid tumours

ATC CodeN/A